Changing the face
of medical research
With its in-depth understanding of human stem cells and its proprietary technology of haploid human embryonic stem cells (HhESCs), NewStem intends to change the paradigm of life sciences and the way we develop diagnostics, therapeutics and reproductive medicine.
NewStem is a biopharmaceutical company focused on human Pluripotent Stem Cells (hPSCs) in general, and Haploid human Pluripotent Stem Cells (HhPSCs), in particular. These cells have the potential to change the face of medical research as they play a pivotal role in regenerative medicine, disease therapy and cancer research. (Nature, Sagi et al., 2016)
NewStem is currently the only company worldwide to develop products based on this innovative, paradigm-changing proprietary technology.
NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HhPSCs and HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling.
The company’s products and technologies were exclusively licensed from Yissum, Hebrew University’s technology transfer company and The New York Stem Cells Foundation, based on the findings and inventions of Prof. Nissim Benvenisty, Director of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem. NewStem is currently developing a personalized diagnostic for early detection of anti-cancer drug resistance and is collaborating with life sciences companies for the development of drugs and reagents.
As featured in:
Ayelet Dilion Mashiah
Ms. Dilion-Mashiah is CEO of NewStem and has served in executive leadership roles in the Life Sciences and Pharmaceutical industries for the past 16 years. Prior to joining NewStem in 2016, she served as CEO of BioMAS from 2011 to 2016. She previously served as CEO of Do-Coop Technologies from 2007 to 2011 after four years as Director – Corporate Economic Development at Teva Pharmaceuticals Industries.
Prof. Nissim Benvenisty
CSO, Founder and Member of the Board
Prof. Benvenisty Chief Science Officer of NewStem, the Herbert Cohn Chair in Cancer Research at the Hebrew University, and the Director of the Azrieli Center for Stem Cells and Genetic Research. His research focuses on stem cell biology, tissue engineering, human genetics and cancer research. He is a member of the steering committee of the International Stem Cell Initiative and the Board of Directors of the International Society for Stem Cell Research. Prof. Benvenisty has been awarded the Foulkes Prize (London), the Hestrin Prize, the Teva Prize, and the Kaye Prize. He earned his M.D. and Ph.D. degrees from the Hebrew University and conducted postdoctoral studies at Harvard University.
Dr. Yaron Daniely
Chairman of the Board
Dr. Yaron Daniely is the CEO and President of Yissum, Hebrew University's renowned Technology Transfer Company. He is also the co-chairperson of the Israel Technology Transfer Network – ITTN. Before joining Yissum in 2017, he served for eight years as President, CEO and Chairman of Alcobra Ltd (NASDAQ: ADHD). Prior to his appointment at Alcobra, Yaron held a number of leadership positions, including President and CEO of NanoCyte Inc., General Manager and VP of Business Development at Gamida Cell Ltd (NASDAQ:GMDA), and co-founder and Director of Bioblast Ltd. (NASADQ:ORPN).
Yaron earned his PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, Yaron served as a Visiting Fellow at the NIH, and as an American Cancer Society Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Yaron also holds an MBA degree from the Technion-Israel Institute of Technology.
Member of the Board
Mr. Loeb has over 35 years of business, money management and investment banking experience. He has been the Managing Member of Leap Tide Capital Management LLC since 2007 and has served as President and CEO of Acorn Energy, Inc. since January 2016 and as a Director since August 2015. Prior, he served as Managing Director at Jefferies & Company, Inc. from 2002 to 2004. From 1994 to 2001, he served as Managing Director at Dresdner Kleinwort Wasserstein, Inc. (formerly Wasserstein Perella & Co., Inc.). He's also been a Director of several other public companies including American Pacific Corporation; Pernix Therapeutics Holdings Inc. (formerly, Golf Trust of America, Inc.); TAT Technologies, Ltd.; and Keweenaw Land Association, Ltd.